
    
      The goals of this study are to determine the following:

        -  To estimate the proportion of patients with a complete cytogenetic response (CCR) within
           each patient group

        -  To estimate the proportion of patients with a substantial molecular response (SMR)
           within each patient group

        -  To evaluate the frequency and severity of adverse events.

        -  To assess the feasibility of AG-858 production.
    
  